Tweet
J Infect Dis. 2018 Dec 14. doi: 10.1093/infdis/jiy723. [Epub ahead of print]
Prevention of influenza hospitalization among adults in the US, 2015-16: Results from the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
Ferdinands JM1, Gaglani M2, Martin ET3, Middleton D4, Monto AS3, Murthy K2, Silveira FP4, Talbot HK5, Zimmerman R4, Alyanak E1, Strickland C1, Spencer S1, Fry AM1; HAIVEN Study Investigators.
Author information
Abstract
Background:
Evidence establishing effectiveness of influenza vaccination for prevention of severe illness is limited. The US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) is a multi-year test-negative case-control study initiated in 2015-16 to estimate effectiveness of vaccine in preventing influenza hospitalization among adults.
Methods:
Adults aged ≥18 years admitted to eight US hospitals with acute respiratory illness and testing positive for influenza by PCR were cases; those testing negative were controls. VE was estimated with logistic regression adjusting for age, comorbidities and other confounding factors and stratified by frailty, two-year vaccination history, and clinical presentation.
Results:
We analyzed data from 236 cases and 1231 controls; mean age was 58 years. Over 90% of patients had ≥1 comorbidity elevating risk of influenza complications. Fifty percent of cases and 70% of controls were vaccinated. Vaccination was 51% (95%CI 29, 65) and 53% (95%CI 11, 76) effective in preventing hospitalization due to influenza A(H1N1)pdm09 and influenza B virus infection, respectively. Vaccine was protective for all age groups.
Conclusions:
During the 2015-16 US influenza A(H1N1)pdm09-predominant season, we found that vaccination halved the risk of influenza-association hospitalization among adults, most of whom were at increased risk of serious influenza complications due to comorbidity or age.
PMID: 30561689 DOI: 10.1093/infdis/jiy723
Prevention of influenza hospitalization among adults in the US, 2015-16: Results from the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
Ferdinands JM1, Gaglani M2, Martin ET3, Middleton D4, Monto AS3, Murthy K2, Silveira FP4, Talbot HK5, Zimmerman R4, Alyanak E1, Strickland C1, Spencer S1, Fry AM1; HAIVEN Study Investigators.
Author information
Abstract
Background:
Evidence establishing effectiveness of influenza vaccination for prevention of severe illness is limited. The US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) is a multi-year test-negative case-control study initiated in 2015-16 to estimate effectiveness of vaccine in preventing influenza hospitalization among adults.
Methods:
Adults aged ≥18 years admitted to eight US hospitals with acute respiratory illness and testing positive for influenza by PCR were cases; those testing negative were controls. VE was estimated with logistic regression adjusting for age, comorbidities and other confounding factors and stratified by frailty, two-year vaccination history, and clinical presentation.
Results:
We analyzed data from 236 cases and 1231 controls; mean age was 58 years. Over 90% of patients had ≥1 comorbidity elevating risk of influenza complications. Fifty percent of cases and 70% of controls were vaccinated. Vaccination was 51% (95%CI 29, 65) and 53% (95%CI 11, 76) effective in preventing hospitalization due to influenza A(H1N1)pdm09 and influenza B virus infection, respectively. Vaccine was protective for all age groups.
Conclusions:
During the 2015-16 US influenza A(H1N1)pdm09-predominant season, we found that vaccination halved the risk of influenza-association hospitalization among adults, most of whom were at increased risk of serious influenza complications due to comorbidity or age.
PMID: 30561689 DOI: 10.1093/infdis/jiy723